Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabergoline + clomiphene citrate
- Development stage
- Phase 3
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy used for ovulation induction in women with polycystic ovarian syndrome (PCOS). Cabergoline is a dopamine agonist that inhibits prolactin secretion, while clomiphene citrate is an estrogen receptor modulator that stimulates gonadotropin release. Studies show that this combination significantly improves ovulation and pregnancy rates compared to clomiphene citrate alone, even in women with normal prolactin levels.
02
Targets
DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)ESR1 (ERα)ESR2 (ERβ)
Beyond the preview
Go deeper on cabergoline + clomiphene citrate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabergoline + clomiphene citrate.